Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 8/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.70 |
| ▸ | F10 | P00742 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meribendan SCHEMBL9781483 | 0.92 | PDE3B (0.58) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL10463603 | 0.83 | PDE3B (0.68) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL10769323 | 0.83 | PDE3B (0.72) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL5952845 | 0.82 | PDE3B (0.66) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1649737 | 0.82 | PDE3B (1.00) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL9781456 | 0.82 | PDE3B (0.77) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL8264681 | 0.82 | PDE3B (0.77) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL10922011 | 0.82 | PDE3B (0.66) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL5951657 | 0.82 | PDE3B (0.64) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Hydrochloric Acid SCHEMBL9781446 | 0.82 | PDE3B (0.66) | PDE3BPDE3AABCB11MAOAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2022123511-A1 | A COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| US-20210393857-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-23 | — | — | US | claimed |
| EP-3876871-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | The Regents of the University of California (US) | 2021-09-15 | — | — | EP | claimed |
| US-20190046528-A1 | METHOD OF PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH BY USING PHOSPHODIESTERASE 3 INHIBITOR | SEOUL NATIONAL UNIVERSITY HOSPITAL (KR) | 2019-02-14 | — | — | US | claimed |
| CN-101874907-B | dual drug stent | 科迪斯公司 | 2016-07-06 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2246076-A2 | Dual drug stent | Cordis Corporation (US) | 2010-11-03 | — | — | EP | claimed |
| CN-101874907-A | Dual drug stent | CORDIS CORP | 2010-11-03 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-5026705-A | Benzimidazolylpyridazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1991-06-25 | — | — | US | claimed |
| EP-0193013-B1 | BENZIMIDAZOLYL-PYRIDAZINONES | MERCK PATENT GmbH (DE) | 1989-04-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393857-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | PER2, NCOR2, NR4A2 | PDE3B 899/4885PDE3A 707/4885ABCB11 3748/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE3B 837/4885PDE3A 296/4885ABCB11 2155/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE3B 837/4885PDE3A 296/4885ABCB11 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.